Deepali Kumar1. 1. Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: To highlight the latest evidence for the use of key vaccines that are recommended in organ transplant candidates and recipients. RECENT FINDINGS: Influenza vaccine is the best studied vaccine; factors affecting immunogenicity of this vaccine include time from transplant, use of mycophenolate mofetil and type of transplant. Newer formulations of influenza vaccine are available, but data for these are limited. Updated recommendations include giving conjugated pneumococcal vaccine to adult transplant candidates and recipients followed by the polysaccharide vaccine to increase serotype coverage. Human papillomavirus vaccine should also be given to transplant recipients, although the immunogenicity may be suboptimal. Quadrivalent meningococcal conjugate vaccine needs to be given in special circumstances such as to patients who are starting eculizumab therapy. Live vaccines in general are contraindicated, although increasing safety data are emerging for Varicella vaccine. Herpes Zoster vaccine may be offered prior to transplant, although the utility of this strategy regarding protection from shingles after transplant is not known. Newer vaccines such as inactivated zoster vaccine and vaccines for the prevention of cytomegalovirus are under study. SUMMARY: Immunization for organ transplant recipients is an important part of pretransplant evaluation and the long-term care of the transplant recipient.
PURPOSE OF REVIEW: To highlight the latest evidence for the use of key vaccines that are recommended in organ transplant candidates and recipients. RECENT FINDINGS: Influenza vaccine is the best studied vaccine; factors affecting immunogenicity of this vaccine include time from transplant, use of mycophenolate mofetil and type of transplant. Newer formulations of influenza vaccine are available, but data for these are limited. Updated recommendations include giving conjugated pneumococcal vaccine to adult transplant candidates and recipients followed by the polysaccharide vaccine to increase serotype coverage. Human papillomavirus vaccine should also be given to transplant recipients, although the immunogenicity may be suboptimal. Quadrivalent meningococcal conjugate vaccine needs to be given in special circumstances such as to patients who are starting eculizumab therapy. Live vaccines in general are contraindicated, although increasing safety data are emerging for Varicella vaccine. Herpes Zoster vaccine may be offered prior to transplant, although the utility of this strategy regarding protection from shingles after transplant is not known. Newer vaccines such as inactivated zoster vaccine and vaccines for the prevention of cytomegalovirus are under study. SUMMARY: Immunization for organ transplant recipients is an important part of pretransplant evaluation and the long-term care of the transplant recipient.
Authors: Kathryn Malone; Stephanie Clark; Jo Ann Palmer; Sonya Lopez; Madhura Pradhan; Susan Furth; Jason Kim; Brian Fisher; Benjamin Laskin Journal: Pediatr Transplant Date: 2016-06-22
Authors: Lei Wang; Erik A M Verschuuren; Coretta C van Leer-Buter; Stephan J L Bakker; Anoek A E de Joode; Johanna Westra; Nicolaas A Bos Journal: Front Immunol Date: 2018-07-16 Impact factor: 7.561